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Abstract 
The European CRT Survey 
Aims: The European Cardiac Resynchronization Therapy (CRT) Survey was a joint initiative 
taken by the Heart Failure (HFA) and the European Heart Rhythm (EHRA) Associations of 
the European Society of Cardiology (ESC) designed to evaluate the current implantation 
practice of Cardiac Resynchronization Therapy (CRT) in the participating countries.   
Methods: Patients who had a successful CRT implantation were enrolled from 141 centres 
in 13 countries between November 2008 and June 2009.  The participating countries were 
Austria, Belgium, France, Germany, Ireland, Israel, Italy, the Netherlands, Norway, Spain, 
Sweden, Switzerland and UK.  Baseline demographics, clinical and implantation data were 
collected using electronic case report form (eCRF) with a follow-up of approximately one 
year (9-15 months). Centres were divided into high and low volume categories and their 
patient selection and implantation practice was analysed. Outcomes in de novo 
implantations were compared to upgrades from permanent pacemakers (PPM) and 
implantable cardioverter defibrillators (ICDs). The follow-up data contained clinical 
outcomes including symptom severity, cardiovascular hospitalization and survival. 
Results: 2438 patients were enrolled and follow-up data acquired from 2111 patients (87 
%). The population included important groups of patients poorly represented in 
randomized clinical trials (RCTs), including very elderly patients, those with prior device 
implantation, atrial fibrillation and QRS duration < 120 ms.  
Significantly more CRT implantation in patients with mild symptoms and narrow QRS width 
was reported at high volume centres. Similar improvement in New York Heart Association 
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(NYHA) class, similar reduction in QRS duration and low and similar total and cause specific 
mortality was observed between upgrades and de novo implantations.  
Investigators reported substantial improvement in NYHA functional class at follow up and 
patients reported improvement in self-assessed global condition. During follow-up, 207 (10 
%) patients died, 346 (16 %) were hospitalized and 501 (24 %) died or were hospitalized. 
NYHA functional class III/IV, atrial fibrillation, ischaemic aetiology and device type (CRT-P) 
were associated with poor survival. Predictors of CV hospitalization and the combined end 
point of CV hospitalization or mortality were NYHA functional class III/IV and atrial 
fibrillation. Women had a better outcome as did patients who had a CRT-D device. 
Conclusions: The CRT Survey provided important information describing current European 
implantation practice at the time of inclusion. High-volume centres were more explorative 
in their implantation practice than low-volume centres. Patients undergoing upgrades from 
existing devices (PPM and ICDs) had similar outcomes and complications rates compared to 
de novo implantations. Outcomes including death and hospitalization during 1 year follow-
up in this European CRT survey were consistent with results from clinical trials of CRT. At 
one year follow-up, 81 % of patients who received a CRT device considered their symptoms 
improved compared to the pre-implant assessment. This is a prospective, observational 
study of successful CRT implantations and the results must be interpreted with appropriate 
conservatism.  
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1. Introduction 
1.1 Cardiac resynchronization therapy (CRT) 
Cardiac resynchronization therapy (CRT) was introduced in 1994 following  an anecdotal 
experience on a single patient with dramatic effects(1). The Multicite Stimulation in 
Cardiomyopathies (MUSTIC) trial conducted in 2001 was the first randomized trial with 
cross-over design in the field of CRT which documented reduced heart failure 
hospitalizations, improved NYHA functional class, exercise distance and peak oxygen 
uptake(2). In 2002, the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) 
further demonstrated reduction in  heart failure hospitalizations, improvement in left 
ventricular ejection fraction and exercise capacity(3). Comparison of Medical Therapy 
Pacing and Defibrillation in Heart Failure (COMPANION) trial conducted in 2004 was the 
first to demonstrate improvement in the combined end point of death and hospitalizations 
followed by Cardiac Resynchronization-Heart Failure (CARE-HF) trial which demonstrated 
survival benefits in 2005(4, 5). 
CRT is indicated in patients with symptomatic heart failure (NYHA III and IV) despite 
adequate medical treatment, a QRS duration ≥ 120 ms and left ventricular ejection fraction 
(LVEF) ≤ 35 %. The 2007 ESC/EHRA Guidelines for Cardiac Pacing(6), the 2008 ESC Heart 
Failure Guidelines(7) and the 2008 ACC/AHA/HRS Guidelines for Device Therapy(8) provide 
a class I recommendation with level of evidence A for CRT with or without an ICD in order 
to improve survival and reduce morbidity. More recent studies, REsynchronization reVErses 
Remodeling in Systolic Left vEntricular Dysfunction (REVERSE), Multicenter automatic 
defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) and 
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Resynchronization-Defibrillation for Ambulatory Heart Failure trial (RAFT) (9-11) have 
explored the use of CRT in patients with mild symptoms, wide QRS complex and LV 
dysfunction and reported favourable outcomes. The results of REVERSE and MADIT-CRT 
have  led to an expansion of the indications as described in the recent update from the ESC 
committee on practice guidelines(12). 
 
Figure 1: Biventricular Pacing for Cardiac Resynchronization Therapy (figure taken from 
NEJM(13)) 
The implantation rate of both CRT-P and CRT-D devices has increased in Europe from 2004-
2008(14). However there are substantial regional, national and centre based differences in 
implantation practice. The decision to include ICD’s in CRT’s is a big challenge in daily 
clinical practice due mainly to lack of proper evidence. Guidelines provide limited guidance 
on which patients should have CRT-P or CRT-D, reflecting the lack of prospective 
randomized clinical trials (RCTs) designed to compare the efficacy of the two types of 
devices(15-17). 
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1.2 Surveys and registries compared to randomized 
controlled trials (RCTs) 
Cross-sectional surveys are snapshots of clinical practice often designed to evaluate 
implementation of recommendations suggested by guidelines. They are usually performed 
for a specified period of time with or without a planned follow-up.  
Non-randomized prospective registries document allocation of treatment in consecutive 
patients and measure outcomes in a defined cohort. They usually involve follow-up over 
time(18). In contrast, randomized controlled trials are designed and powered to evaluate 
new interventions in a blinded, controlled fashion.  
The advantages of surveys and registries are that they capture data from a more 
heterogeneous population and should reflect actual clinical practice and answer different 
questions (18-20). Previous assumptions suggesting that observational studies report 
greater treatment benefit have been shown not to be valid (21, 22). The disadvantages are 
potential selection bias, incomplete data collection and may underestimate adverse 
experience if proper precautions are not taken at the planning phase (18, 23). 
Although randomized controlled trials have specific hypothesis in well-defined populations, 
they have their limitations too. The disadvantages are that they select patients according to 
strict inclusion criteria and exclude elderly patients and patients with important 
comorbidities. In addition to this, often strong focus is attributed to statistical significance 
without taking into account clinical significance (24).   
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1.3 Selection of patients to CRT and response to treatment 
Predicting response in patients treated with CRT is a challenge in daily clinical practice. The 
definition of response needs also further refinement and should not be confused with 
outcomes(25). There is also poor agreement between the parameters selected to define 
response(26).  
Several patient selection criteria have been suggested to predict response. A LBBB pattern 
(electrical dyssynchrony) in patients with symptomatic heart failure as a surrogate indicator 
of dyssynchronous left ventricular contraction has shown to be robust criteria in many 
trials. A recent meta-analysis of existing randomized trials identifies QRS duration over 150 
ms as a strong predictor of reducing adverse clinical events(27). Studies on benefit of CRT in 
patients with narrow QRS width with or without evidence of echocardiographic mechanical 
dyssynchrony report conflicting results and it remains to be addressed in further clinical 
trials(28-34). 
Imaging and especially, echocardiographic parameters of mechanical dyssynchrony have 
been utilized to help finding proper candidates. However, identifying single and 
reproducible echocardiographic measure of dyssynchrony remains to be a challenge (35, 
36).   
1.4 Upgrading from permanent pacemakers and ICDs to 
CRT 
Studies have demonstrated that right ventricular (RV) pacing is associated with heart 
failure-related hospitalization and death with direct relation to the cumulative percentage 
of RV pacing (37-39). Upgrading existing systems (permanent pacemakers and ICDs) to CRTs 
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in patients with deteriorated left ventricular function can improve LV functions and 
symptoms by a similar magnitude as seen in de novo implantations (40-43). However, 
upgrading existing pacemakers carries higher risk of subsequent complication than 
performing a de novo implant(44, 45), due to potential limited venous access, risks of 
damage to or requirement for extraction of old leads and infection(46, 47). Despite the fact 
that an upgrade procedure is not entirely risk free, no randomized placebo-controlled trial 
of upgrading to CRT has been performed in patients with RV pacemakers (or ICDs) and 
heart failure. 
1.5 Initiation of the European CRT Survey 
Because of the existing variations in practice, the Heart Failure (HFA) and the European 
Heart Rhythm (EHRA) Associations of the ESC jointly initiated this CRT Survey with the 
objective of describing current European practice and routines associated with CRT-P/CRT-
D implantations.  Sampling was done in 141 centres from 13 countries: Austria, Belgium, 
France, Germany, Ireland, Israel, Italy, the Netherlands, Norway, Spain, Sweden, 
Switzerland and UK.  
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2. Objectives of the thesis  
2.1 General objectives 
To assess the current implantation practice of CRT devices in a wide sampling from 
European implanting centres. 
2.1.1 Specific objectives 
1. Rationale and design of the Survey 
2. To describe the populations being implanted with CRT devices with regard to 
patient selection, implantation routines and techniques, peri-procedural 
complications and in hospital course 
3. To explore the variations in practice based on the volume of implanting centres 
4. To assess outcomes of patients upgraded from previous devices (pacemakers and 
ICDs) compared to de novo implantations 
5. To report outcomes during the 1 year (9-15 months) follow-up 
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3. Subjects 
The study recruited 2438 patients from 141 centres in 13 countries.  
The volume based analysis included 2392 patients from 136 centres. 5 centres had missing 
volume information and therefore were excluded from the analysis. 
692 patients were upgraded from either conventional pacemakers or ICDs. 430 of these 
patients had ventricular paced rhythm. The upgraded patients were compared and 
contrasted with regards to procedural details and outcomes with de novo implantations.  
Follow-up data was acquired from 2111 patients (87 % of the Survey cohort).   
 
Figure 2: participating countries and patients per country 
Nor 126 
Swe 321 
UK 201 
Ire 47 
 Spa 131 
Ita 571 
Germ 291 
Aus 156 
Nethe 114 
Isra 195 
Bel 43 
Fra 160 Swit 83 
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4. Methods 
A Scientific Committee was established comprised of 13 professionals from the fields of 
heart failure, electrophysiology and echocardiography and co-coordinated by Professor 
Kenneth Dickstein (HFA) and Professor Silvia Priori (EHRA).  Two National Coordinators 
(appendix 1) from the participating countries (one each from the fields of heart failure and 
electrophysiology) were selected to facilitate patient inclusion and follow-up in their 
respective countries.  
An electronic case report form (eCRF) was developed by the Scientific Committee.   
All CRT implanting centres in the selected 13 countries were invited to participate into the 
Survey and were asked to complete a one-time site questionnaire describing the type and 
size of the centre, reference area population, facilities, and number of invasive procedures 
performed.  141 of the centres responded and that is approximately 18 % of the invited 
centres. Germany and Sweden have on-going device registries which include CRTs and 
capture most of the information contained in the CRT Survey eCRF. With permission from 
both of the Steering Committees (appendix 2), CRT data collected consecutively in these 
two registries during the time frame were merged into the CRT Survey database. 
 
Inclusion of patients started 1st November 2008 and ended 30th June 2009. All consecutive 
patients successfully implanted with a new CRT-P, CRT-D or upgrades were eligible. The 
procedure itself identified the patient as a Survey candidate. A successful implantation was 
defined as a completed procedure. Patients screened but not successfully implanted were 
not entered into the Survey. Ethical approval and written informed consent were obtained 
according to the rules for clinical investigations in each participating country at the time of 
initiation of the study. 
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A central data-base was created at the data management centre, Institut für 
Herzinfarktforschung in Ludwigshafen an der Universität Heidelberg, Germany which also 
maintained and interrogated the database and performed analyses. A web site www.crt-
survey.org supported by the ESC Web department provided all the relevant documents and 
permitted online data entry. Tessa Baak (Stavanger Heath Research Foundation) and Tobias 
Limbourg (Institut für Herzinfarktforschung in Ludwigshafen) followed the daily inclusion 
activity and provided advice regarding operational issues.   
Centre volume information was acquired from the one time site questionnaire collected at 
the initiation of the Survey. ICD implantation rate the previous year was chosen as the basis 
for assignment of centre volume category as it showed to be the most appropriate. A 
median of 120 ICDs were implanted at the participating centres. Centres implanting ൑ 120 
ICDs per year were therefore regarded as low volume and centres implanting ൐120 ICDs 
per year were regarded as high volume centres. 42 (30 %) centres were classified as high 
volume and 94 (67 %) as low volume centres with the average CRT implantation rate of 29 
and 13 respectively. Complete centre volume information was not available in 5 (4 %) of 
the participating centres.  A total of 1200 CRT devices were implanted at high volume 
centres and 1192 CRT devices at low volume centres. 
Analysis of upgrades versus de novo implantations included 2367 CRT implant procedures 
of whom 692 (28%) were upgrades to CRT.  
The 1 year (9-15 months) follow-up data were collected through the routine device follow-
up schedule and the window of 6 months was allowed in order to give enough time to 
capture data from routine device follow-ups. 
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5. Statistics 
All statistical work and database management was performed at Institut für 
Herzinfarktforschung in Ludwigshafen an der Universität Heidelberg, Germany.  
Absolute numbers and percentages are shown for categorical variables to describe the 
patient population, and medians with inter-quartile range or means with standard 
deviations for continuous variables. Binary variables (yes/no response variables) were 
compared between subgroups by the Pearson chi-square test and continuous variables 
(numeric values) by the Mann-Whitney-Wilcoxon-test. Odds ratios and confidence intervals 
were calculated where appropriate. Descriptive statistics were calculated for the available 
cases where it applied. A significance level of p < 0.05 was assumed for the statistical tests 
and all P-values are results of two-tailed tests. Kaplan Meier survival estimates and logistic 
regression analyses between the variables were performed as required (paper 4 and 5). All 
statistical analyses were performed using SAS statistical software, version 9.1 (Cary, North 
Carolina, U.S.A.) 
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6. Summary of results 
6.1 Paper I 
Paper 1 is the rationale and design paper which summarized the difference in CRT 
implantation practice in Europe reporting the variations in number of implants per country 
and the ratio between CRT-D and CRT-P. The information provided in this paper together 
with the protocol and eCRF was important document for invited centres providing the 
necessary background material for the decision to participate in the Survey. 
6.2 Paper II 
Results 
2438 patients were enrolled into the Survey. The mean age of patients was 68 years ±10  
and 31 % were ≥ 75 years. 78 % were in NYHA functional class III or IV and 22 % in I or II.  
The mean ejection fraction was 27 % ± 8 and the mean QRS duration 157 ms ± 32.  
QRS duration was < 120 ms in 9 %. Atrial fibrillation was reported in 23 %. 26 % of  
patients had a previously implanted permanent pacemaker or ICD. 76 % of  
procedures were performed by an electrophysiologist. 82 % had an elective admission  
for implantation and the median duration of hospitalisation was 3 days (IQR 2-7).  73  
% received a CRT-D device which was more often implanted in men, younger  
patients and patients with ischaemic aetiology. The mean QRS duration was reduced to 133  
ms ± 27 (p<0.0001) at discharge. Peri-procedural complication rates were comparable  
to the rates reported in randomized trials. 
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Conclusions - This CRT Survey provides important information describing current European 
practice with regard to patient demographics, selection criteria, procedural routines and 
status at discharge. These data should be useful for benchmarking individual patient 
management and national practice against wider experience. 
6.3 Paper III 
Results - A total of 1200 CRT devices were implanted at high volume centres and 1192 CRT 
devices at low volume centres. 42 (30 %) centres were classified as high volume and 94 (67 
%) as low volume centres with the average CRT implantation rate of 29 and 13respectively. 
Complete centre volume information was not available in 5 (4 %) of the participating 
centres.  Germany, the Netherlands and UK had the highest percentage of high volume 
centres while Belgium, Switzerland, Austria, Sweden and Italy the highest percentage of 
low volume centres. No differences were noted with regard to sex, age or peri-procedural 
and device related complications between high volume and low volume centres. High 
volume centres implanted CRT devices in significantly more patients with mild symptoms 
and a narrow QRS width. The procedure and fluoroscopy times were substantially longer at 
low volume centres and devices were more frequently implanted by surgeons and 
interventional cardiologists. Patients stayed longer in hospital in low volume centres with a 
median of 4 (2-9) vs. 2 (2-6) days. 
Conclusions - High volume centres explore newer indications in their CRT practice  
and implant devices more frequently in patients with mild symptoms and narrow  
QRS durations. Electrophysiologists dominate implantation practice at high volume  
centres and duration of hospitalisation is substantially shorter at these centres. 
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6.4 Paper IV 
Results - This analysis included 2367 CRT implant procedures of whom 692 (28%) were 
upgrades to CRT. Distribution of NYHA functional class and left ventricular function were 
similar between the groups. Procedural duration was also similar, although fluoroscopy 
time was shorter in the ‘upgrades’. There was no difference in the frequency of peri-
procedural complications. There were similar improvements in NYHA functional class and 
similar reduction in QRS duration but more patients reported unchanged global patients 
assessment status in the upgraded group. Total and cause-specific mortality at one year 
was low and the same in both groups. 
Conclusions – More than one quarter of all CRT procedures are upgrades from existing 
systems, although this group has not been subject to randomized clinical trials.  Our data 
suggest that there are no significant differences in clinical outcomes or complication rates 
between upgrades and de novo procedures.  
6.5 Paper V 
Results - 2438 patients were enrolled and follow-up data acquired from 2111 patients (87 
%). The population included important groups of patients poorly represented in 
randomized clinical trials, including very elderly patients and those with previous device 
implantation, atrial fibrillation and/or QRS duration < 120 msec.   
Investigators reported substantial improvement in NYHA functional class at follow-up. 
Patient self-assessment indicated that 81 % of patients felt much better/a little better, 16 % 
reported no change and 4 % reported worsening of their status. During follow-up, 207 
patients died (10 %), 346 (16 %) were hospitalized and 501 (24 %) died or were 
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hospitalized.  NYHA functional class III/IV, atrial fibrillation, ischemic aetiology, and device 
type (CRT-P) and were associated with poor survival. Predictors of CV hospitalization and 
the combined end point of CV hospitalization or mortality were NYHA functional class III/IV 
and atrial fibrillation. 
 COMPANION 
(4) 
CARE-HF 
(5, 48) 
REVERSE 
(9, 49) 
MADIT-CRT 
(10) 
RAFT 
(11) 
CRT Survey 
No of patients (CRT-P/CRT-D) control groups 1212 
308 
409 
404 
419 
191 
1089 
731 
894 
904 
2438 
0 
Mean  follow-up (mo) 14.8-16.5 37.4 12 28.8 40 12 
Baseline characteristics (%) 
   Mean age (years) 
   Men 
   Ischaemic heart disease 
   Atrial fibrillation 
   Previous device  
   Ventricular  paced rhythm  
   RBBB  
   QRS duration (ms) 
   Mean LVEF  
   NYHA class 
      I/II 
      III/IV  
 
67 
67 
55  
0ᵟ 
0ᵟ 
0ᵟ 
10 
160 
22 
 
0ᵟ 
100 
 
66 
74 
38  
0ᵟ 
0ᵟ 
0ᵟ 
0ᵟ 
165 
24.8 
 
0ᵟ 
100 
 
62 
79 
55 
0ᵟ 
0ᵟ 
0ᵟ 
10 
153 
27 
 
100 
0ᵟ 
 
65 
75 
55 
0ᵟ 
0ᵟ 
0ᵟ 
13 
65 % > 150 
24 
 
100 
0ᵟ 
 
66 
83 
67 
13 
NAᵟᵟ 
8 
9 
158 
23 
 
80 
20 
 
68 
76 
51  
23  
28 
18 
6 
160 
26  
 
22 
78 
Outcomes in the CRT-D/P treated  group (n, %) 
      Mortality during follow-up 
      Death or hospitalization for HF 
 
246 (20.3) 
449 (37.1) 
 
101 (24.7)  
118 (28.9)ᶲ  
 
  9 (2.2) 
26 (6.2) 
 
  74 (6.8) 
187 (17.2) 
 
186 (20.8) 
297 (33.2) 
 
207 (9.8)§ 
501 (23.7)£ 
ᶲ  combined mortality and hospitalization data from CARE-HF 2005 publication (5)                                                                   
§  follow-up data available for 2111 (86.6 % of the total cohort) 
£  hospitalization data available for 1797 (73.7 % of the total cohort)  
ᵟ   these were exclusion criteria in the trials 
ᵟᵟ  previous ICDs were exclusion criteria in RAFT and only paced rhythm is reported 
 
 
Conclusions - Outcomes including death and hospitalization during 1 year follow-up in this 
European survey were consistent with results from clinical trials of CRT. At one year follow-
up, most patients who received a CRT device are alive and feel they have improved 
compared to their pre-implant assessment. This is an observational survey should not be 
used to try to define whether subgroups did or did not respond to therapy.  
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7. Discussion 
This Survey, which was jointly initiated by the Heart Failure (HFA) and the European Heart 
rhythm (EHRA) Associations of the European Society of Cardiology (ESC), is the largest 
available on CRT implantation practice in Europe which included 2438 patients in 13 
countries from 141 centres. The primary objective of the Survey was to describe current 
practice and routines associated with consecutive and successful CRT-D/CRT-P 
implantations in the participating centres. During the study period, the ESC guidelines on 
device treatment for heart failure were updated to include patients with milder symptoms, 
atrial fibrillation and conventional pacemaker indications (50). 
The first publication was the design and rationale paper which described inclusion criteria 
and contents of the eCRF both at baseline and during follow-up. It was important document 
aimed to be invitation and information to the prospective participating centres(51).  
The baseline and short term outcomes at the index hospitalization were presented in the 
second publication from this survey(52). The population included important groups of 
patients poorly represented in randomized clinical trials, including very elderly patients and 
those with prior device implantation, atrial fibrillation and/or QRS duration < 120 msec. 
The target populations and diagnostic investigations that would best select patients likely 
to respond favourably from intervention have not been identified(53). QRS duration, a 
measure of electrical dyssynchrony has formed the basis inclusion criteria in randomized 
clinical trials. Currently, none of the commonly employed echocardiographic measurements 
appear robust enough to accurately evaluate mechanical dyssynchrony or predict clinical 
response (36). Based on clinical experience and intuition, clinicians frequently extrapolate 
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the data from randomized clinical trials to wider populations which is appropriate when 
clinical evidence is lacking and no opportunity to enrol the patient into a relevant RCT 
exists.  It is evident from the description of the patient characteristics of the population 
included in this Survey that clinicians are actively exploring wider indications.  
Generally our cohort is remarkably similar to the cohorts recruited in randomized clinical 
trials. A consistent finding is the low proportion of women receiving CRTs both in 
randomized clinical trials and this Survey. Aggressive medical management was confirmed 
with high percentages of patients treated with diuretics, ACE inhibitors, ARBs, beta 
blockers, and aldosterone antagonists. Importantly in this real-world population, 
complication rates were similar to the rates reported in RCTs. On the other hand the peri-
operative complication rate is not negligible and must be weighed against the potential 
benefits when considering CRT therapy in patients in mild symptoms.  
The third publication from this Survey’s cohort investigated whether the volume of 
implants per centre was a determinant of the propensity to use devices for “off-label” 
indications and reported that high volume centres explore newer indications in their CRT 
practice and implant devices more frequently in patients with mild symptoms and narrow 
QRS durations. Centres were categorized into low volume (൑120 implantations/year) and 
high volume (൐120 implantations/year) based on median ICD implantation the previous 
year which was found to be the most appropriate. 
There is substantial variation across Europe with regard to adoption of the 
recommendations by guidelines (54). Specifically, practice varies widely with regard to 
decisions concerning device type (CRT-P/CRT-D)(55) due to lack evidence to assist the 
clinicians in making decisions regarding device type. Comparison based on centre volume 
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and experience in this Survey provides important information regarding existing variations 
in practice. Local reimbursement policies, the existence of national guidelines and high 
number of conventional ICD implantations are identified as important factors for national  
practice variations while GDP or health care spending appears to have a minor  
role(54). However, basing national practice on the number ICD implantations should  
be approached cautiously as a recent study from the USA has showed non-evidence  
based practice(56).  
 
The fourth publication addressed the issue of upgrading to CRT from permanent 
pacemakers (PPM) and ICDs comparing to de novo implantations. The Survey cohort 
included 692 patients (28 %) with previous devices. A paced ventricular rhythm was 
reported in 430 patients (62 %) at the time of inclusion. Our data suggest that there are no 
significant differences in clinical outcomes or complication rates between upgrades and de 
novo procedures.  
This practice is a substantial extrapolation beyond the evidence. Small studies have 
previously demonstrated favourable short and long term outcomes in patients receiving 
CRT as an upgrade to a standard RV pacemaker(40, 57) and the practice of upgrading 
pacing systems to those capable of delivering CRT is mentioned in guidelines, albeit with a 
class IIa (level of evidence: C) recommendation. Our analysis provides some reassurance 
that, upgrading a previous device to one capable of providing resynchronization therapy 
seems to be associated with a similarly modest medium-term complication rate to a de 
novo implant. Nevertheless, the efficacy of CRT in this patient group is not established with 
trial data (37, 58, 59). The recent RAFT trial that included a small number (135/1798) of 
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previously paced patients but subgroup analysis did not reveal a clinical benefit of 
upgrading to CRT (11). 
Many patients receiving RV pacemakers are elderly and have a background of ischaemic 
heart disease or hypertension, both of which contribute to the development of heart failure. 
In addition however, RV pacing induces intra and inter-ventricular dyssynchrony(60), which 
seems to be similar to that of left bundle branch block (LBBB)(40, 61), although recent tissue 
tracking data suggest that intra-mural dyssynchrony might be different in patients paced 
from the RV apex(62). The imposition of abnormal contractile timing can lead to altered 
regional blood flow and wall stress (63-65). The severity of these perfusion abnormalities, 
the regional wall motion abnormalities and the associated deterioration in global left 
ventricular function are directly related to the duration(63) and cumulative percentage of RV 
pacing(39), but can be identified in some individuals after only 18 months of pacing(66). The 
induction of dyssynchrony by RV apical pacing seems therefore to lead to adverse LV 
remodelling, LV dilatation and asymmetrical hypertrophy (67), which can lead to the 
induction or progression of LV dysfunction (68). One recent study of patients in need of 
ventricular pacing due to bradycardia and with normal LVEF at the time implantation 
support that ventricular function assessed at 12 months was worse in patients randomized 
to RV compared to CRT pacing(69).  The data from the present Survey confirm data from 
smaller studies that patients with RV pacing-associated ventricular dysfunction seem to have 
slightly better overall LV function and more left ventricular hypertrophy (LVH)(40, 62), which 
might be the morphological characteristics of the increasingly recognised ‘pacing 
cardiomyopathy’. 
Despite differences in baseline LVEF, the present data suggest that the symptomatic 
response is similar in patients with and without a previous device, although a slightly higher 
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proportion of patients self-reported unchanged total global assessment in the upgraded 
group. NYHA functional class and total and cause-specific mortality at one year were similar 
between the groups. This is reassuring since a randomized, placebo-controlled trial in RV-
paced patients with class III and IV heart failure is unlikely to be performed. The fact that 
the European CRT survey outcome data for patients undergoing upgrades compare 
favourably with those for the de novo group in whom the benefit of CRT implantation has 
already been confirmed in randomized studies suggests that even in the absence of a 
randomized trial, upgrade procedures could receive more support in guidelines.  
As discussed, patients with RV pacing systems, especially those with unavoidable RV apical 
pacing are at high risk of LV dysfunction. The next logical step is to explore whether 
patients with underlying LV dysfunction, an absolute indication for rate support and mild or 
absent symptoms benefit from CRT at initial implant (70) or elective upgrade before they 
deteriorate. Whether taking the opportunity provided by generator replacement to implant 
an LV lead in patients with evidence of LV dysfunction and few symptoms will reduce 
subsequent risk of hospitalisation or death or need for upgrade should be tested in a 
prospective randomised, controlled trial. 
The final manuscript from this Survey presents outcomes during the 1 year (9-15 months). 
Follow-up data including vital status were available for 2111 patients which accounts for 87 
% of the total survey population. During the course of follow-up, 207 (10 %) patients died, 
346 (16 %) patients were hospitalized for cardiovascular reasons and 501 (24 %) patients 
died or were hospitalized. The findings in this Survey are consistent with results from 
previous clinical trials. 81 % of the patients report improvement in self-assessed global 
condition.   
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Women are less represented than men in this Survey (24 %) as is evident in several studies 
(5, 9-11). However, the outcomes of treatment with CRT devices appear to be better in 
women than in men which may be associated with higher proportion of non-ischaemic 
aetiology in women.  
Studies comparing survival outcomes between recipients of CRT-D and CRT-P are lacking. 
Findings from this Survey clearly identify allocation to device type CRT-D as important 
prognostic factor for survival both univariate and multi-variate analysis. However these 
findings should be interpreted cautiously since CRT-P recipients in this cohort were older 
(median age 75 vs. 68 years) and the influence of selection is evident. 
Our Survey included 544 patients (23 %) with atrial fibrillation which indicated poor 
outcomes with regards to death, hospitalization for cardiovascular reasons and the 
combination of death or hospitalization. Information on the percentage of cumulative 
biventricular pacing, the extent of AV node ablation post device implantation or up titration 
of medical treatment to assure adequate pacing was not captured in the Survey. The RAFT 
trial included 115 patients (13 %) with atrial fibrillation or flutter (11). No benefit of CRT 
treatment was observed in this population compared to ICD therapy, though the Survey 
population is not directly similar to the RAFT population. Inadequate measure to assure 
pacing may explain this observation which differs from previous findings reporting benefit 
of CRT treatment in populations with atrial fibrillation (71-74).  
7.1 Strengths of the survey 
One of the strengths of this Survey is inclusion of patients which are similar to the patients 
in daily clinical practice who have not been adequately addressed in randomized clinical 
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trials. Importantly, patients with previous device, substantial number of patients over the 
age of 75 years, patients with atrial fibrillation, RBBB, mild symptoms and narrow QRS 
width are included reflecting the dilemma which exists in tailoring treatment to individual 
patients. Important recent clinical and implantation data are collected from 13 countries. 
The results permit individual countries to benchmark their practice against international 
practice. 
7.2 Limitations 
Surveys are important sources of information on how evidence acquired through 
randomized clinical trials are adopted in clinical trials. However, surveys have their own 
limitations which need to be considered during interpretation of the findings which we 
report. Centre participation was voluntary and among all eligible and invited, only 141 
centres responded and recruited patients in the 13 countries.  Although the importance of 
consecutive inclusion was emphasized, we cannot confirm that all patients were included 
consecutively and there is a potential for investigator selection bias. Importantly, only 
successful implantations were entered into the database which selects the patient 
population and could lead to an under-reporting of adverse experience in connection with 
implantation. The accuracy of the data has not been audited. There is a considerable 
variation in the sample size for some of the eCRF variables due to unavailable information, 
incomplete data entry and incomplete overlap between the variables collected in the 2 
device registries and this Survey. The Swedish pacemaker registry data base was 
restructured during the follow-up phase of the Survey which resulted in acquisition of only 
survival data of this particular cohort. 
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Conclusions 
1- The baseline characteristics of patients included were similar to available randomized 
clinical trials cohorts and complication rates were comparable. This Survey has 
demonstrated substantial CRT implantations in populations not addressed in current 
guidelines. 
2- High volume centres are exploring broader indications in their CRT practice and implant 
devices more frequently in patients with mild symptoms and narrow QRS durations. 
3-Outcomes in patients upgraded to CRT from permanent pacemakers (PPM) and ICDs are 
similar to outcomes following de novo implantations. 
4- Outcomes including death and hospitalization during 1 year follow-up in this European 
survey were consistent with results from clinical trials of CRT. At one year follow-up, 81 % 
of patients who received a CRT device considered their symptoms improved compared to 
the pre-implant assessment and 90 % of them were alive. This is a prospective, 
observational study of successful CRT implantations and the results must be interpreted 
with appropriate conservatism.  
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